Koshinski Asset Management Inc. grew its position in Bristol-Myers Squibb Co (NYSE:BMY) by 44.8% in the second quarter, HoldingsChannel reports. The institutional investor owned 9,345 shares of the biopharmaceutical company’s stock after purchasing an additional 2,892 shares during the period. Koshinski Asset Management Inc.’s holdings in Bristol-Myers Squibb were worth $549,000 at the end of the most recent reporting period.
Other large investors have also recently added to or reduced their stakes in the company. JCIC Asset Management Inc. purchased a new stake in shares of Bristol-Myers Squibb in the 1st quarter worth about $25,000. Perennial Advisors LLC acquired a new position in Bristol-Myers Squibb during the first quarter worth about $27,000. CVA Family Office LLC purchased a new stake in shares of Bristol-Myers Squibb in the first quarter valued at about $28,000. MBE Wealth Management LLC acquired a new stake in shares of Bristol-Myers Squibb in the first quarter valued at approximately $41,000. Finally, AlphaCore Capital LLC acquired a new stake in shares of Bristol-Myers Squibb in the first quarter valued at approximately $49,000. 74.20% of the stock is owned by institutional investors and hedge funds.
A number of equities research analysts have commented on the company. Bank of America reiterated a “buy” rating and set a $80.00 target price on shares of Bristol-Myers Squibb in a report on Friday, May 15th. TheStreet lowered Bristol-Myers Squibb from a “b-” rating to a “c+” rating in a research note on Monday, April 13th. ValuEngine downgraded shares of Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a research note on Monday, June 1st. Cfra reaffirmed a “buy” rating and set a $70.00 price target on shares of Bristol-Myers Squibb in a research note on Sunday, July 26th. Finally, Seaport Global Securities assumed coverage on shares of Bristol-Myers Squibb in a report on Tuesday, July 28th. They set an “outperform” rating and a $75.00 price target for the company. One research analyst has rated the stock with a sell rating, four have given a hold rating and thirteen have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $68.93.
Shares of BMY opened at $58.66 on Friday. The firm has a market cap of $132.73 billion, a PE ratio of 72.42, a price-to-earnings-growth ratio of 1.12 and a beta of 0.73. The company’s fifty day moving average is $58.18 and its two-hundred day moving average is $60.16. Bristol-Myers Squibb Co has a fifty-two week low of $44.00 and a fifty-two week high of $68.34. The company has a quick ratio of 1.51, a current ratio of 1.66 and a debt-to-equity ratio of 0.86.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $1.72 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.23. Bristol-Myers Squibb had a return on equity of 30.06% and a net margin of 3.08%. The business had revenue of $10.78 billion during the quarter, compared to the consensus estimate of $10.04 billion. During the same period in the prior year, the firm posted $1.10 EPS. The business’s revenue for the quarter was up 82.1% on a year-over-year basis. As a group, equities research analysts anticipate that Bristol-Myers Squibb Co will post 6.18 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Monday, July 6th will be issued a $0.45 dividend. The ex-dividend date of this dividend is Thursday, July 2nd. This represents a $1.80 dividend on an annualized basis and a dividend yield of 3.07%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 38.38%.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Featured Article: How is net asset value different from market price?
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.